Clinical effect of Rosuvastatin Calcium Tablets combined with Zhibitai in the treatment of hyperlipidemia
TAN Bin1 WU Yi-jun2 YU Bo2
1.Department of Emergency,the Third People′s Hospital of Jingdezhen City,Jiangxi Province,Jingdezhen 333000,China;
2.Department of Cardiovascular Medicine,the Third People′s Hospital of Jingdezhen City,Jiangxi Province,Jingdezhen 333000,China
Abstract:Objective To analyze the value of Rosuvastatin Calcium Tablets combined with Zhibitai in the treatment of hyperlipidemia.Methods One hundred and twenty patients with hyperlipidemia treated in the Department of Emergency and Cardiovascular Medicine in the Third People′s Hospital of Jingdezhen City from September 2019 to August 2020 were selected as research subjects,and they were divided into the observation group(n=60)and the control group(n=60)by the random number method.Observation group was treated with Rosuvastatin Calcium Tablets combined with Zhibitai,and control group was treated with Rosuvastatin Calcium Tablets.The levels of total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C)before and after treatment and the total incidence of adverse reactions of the two groups were compared.Results Before treatment,there were no statistical significances in TC,TG,HDL-C and LDL-C between the two groups(P>0.05).The TC and TG of the two groups after treatment were lower than those before treatment,the differences were statistically significant(P<0.05).The TC and TG of observation group were lower than those in the control group after treatment,the differences were statistically significant(P<0.05).The HDL-C of the observation group after treatment was higher than that before treatment,LDL-C of observation group after treatment was lower than that before treatment,the differences were statistically significant(P<0.05).There were no significant differences in the HDL-C and LDL-C of control group before and after treatment(P>0.05).The LDL-C level in observation group after treatment was lower than that in the control group,and HDL-C level was higher than that in the control group,with statistical significances(P<0.05).There was no statistical significance in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rosuvastatin Calcium Tablets combined with Zhibitai in the treatment of hyperlipidemia has a good effect,not only to improve the level of blood lipid,but also contribute to the stability of atherosclerotic plaque,and does not increase adverse reactions,which is worthy of clinical application.
谭斌;吴一君;余波. 瑞舒伐他汀钙片联合脂必泰治疗高脂血症的临床效果[J]. 中国当代医药, 2021, 28(13): 64-66.
TAN Bin; WU Yi-jun;YU Bo. Clinical effect of Rosuvastatin Calcium Tablets combined with Zhibitai in the treatment of hyperlipidemia. 中国当代医药, 2021, 28(13): 64-66.